10:40 AM EST - Trillium Therapeutics Inc. : Announced that preclinical data from its TTI-622 (SIRPa-IgG4 Fc) immune checkpoint inhibitor program were presented at the 109th Annual Meeting of the American Association for Cancer Research. Trillium Therapeutics Inc.
shares T.TRIL are trading down $0.44 at $8.87.
